Please assess the completion status of the following clinical trial:

Trial Title: Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cytologically or histologically confirmed evidence of epithelial cancer (adenocarcinoma) of the exocrine pancreas~* Metastatic disease~* No prior chemotherapy for pancreatic disease~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2~* Adequate renal, liver and bone marrow functions~Exclusion Criteria:~* Less than 42 days elapsed from prior major surgery (28 days from other prior surgery) to the time of randomization~* Prior treatment with anti-VEGF or VEGF-Receptor-inhibitors~* Uncontrolled hypertension~* Pregnancy or breastfeeding~* Participant with reproductive potential (M/F) without effective method of contraception~The above information is not intended to contain all considerations relevant to potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo and Gemcitabine (Type: PLACEBO_COMPARATOR): Participants with metastatic pancreatic cancer administered Placebo and 1000 mg/m\^2 Gemcitabine.
- Aflibercept and Gemcitabine (Type: EXPERIMENTAL): Participants with metastatic pancreatic cancer administered 4 mg/kg Aflibercept and 1000 mg/m\^2 Gemcitabine.

Based on this trial design, predict the completion outcome and termination type (if applicable).